Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Rural residence and adoption of a novel HIV therapy in a national, equal-access healthcare system.

Ohl M, Lund B, Belperio PS, Goetz MB, Rimland D, Richardson K, Justice A, Perencevich E, Vaughan-Sarrazin M.

AIDS Behav. 2013 Jan;17(1):250-9. doi: 10.1007/s10461-011-0107-8.

2.

Rural residence is associated with delayed care entry and increased mortality among veterans with human immunodeficiency virus infection.

Ohl M, Tate J, Duggal M, Skanderson M, Scotch M, Kaboli P, Vaughan-Sarrazin M, Justice A.

Med Care. 2010 Dec;48(12):1064-70. doi: 10.1097/MLR.0b013e3181ef60c2.

3.

Antiretroviral adherence among rural compared to urban veterans with HIV infection in the United States.

Ohl ME, Perencevich E, McInnes DK, Kim N, Rimland D, Akgun K, Fiellin DA, Skanderson M, Wang K, Justice A.

AIDS Behav. 2013 Jan;17(1):174-80. doi: 10.1007/s10461-012-0325-8.

PMID:
23080359
4.
5.

Geographic access and use of infectious diseases specialty and general primary care services by veterans with HIV infection: implications for telehealth and shared care programs.

Ohl ME, Richardson K, Kaboli PJ, Perencevich EN, Vaughan-Sarrazin M.

J Rural Health. 2014 Fall;30(4):412-21. doi: 10.1111/jrh.12070.

PMID:
24702698
6.

Rural access to clinical pharmacy services.

Patterson BJ, Kaboli PJ, Tubbs T, Alexander B, Lund BC.

J Am Pharm Assoc (2003). 2014 Sep-Oct;54(5):518-25. doi: 10.1331/JAPhA.2014.13248.

PMID:
25216881
7.

VA intensive mental health case management in urban and rural areas: veteran characteristics and service delivery.

Mohamed S, Neale M, Rosenheck RA.

Psychiatr Serv. 2009 Jul;60(7):914-21. doi: 10.1176/appi.ps.60.7.914.

PMID:
19564221
8.

Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.

Elbasha EE, Szucs T, Chaudhary MA, Kumar RN, Roediger A, Cook JR, Opravil M.

HIV Clin Trials. 2009 Jul-Aug;10(4):233-53. doi: 10.1310/hct1004-233.

PMID:
19723611
9.

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.

Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S; SPRING-2 Study Group..

Lancet. 2013 Mar 2;381(9868):735-43. doi: 10.1016/S0140-6736(12)61853-4.

PMID:
23306000
10.

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM; SPIRAL Study Group..

AIDS. 2010 Jul 17;24(11):1697-707. doi: 10.1097/QAD.0b013e32833a608a. Erratum in: AIDS. 2010 Oct 23;24(16):2602.

PMID:
20467288
11.

Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.

Skiest DJ, Cohen C, Mounzer K, Haigney Z, Barker D, Gottlieb M, Bellman PC, Dejesus E, Khanlou H, Ruane PJ, Hsiao CB, Abriola K, Rashbaum B, Bellos N, Ward D, Colson A, Santiago F, Habel A, Garb J.

HIV Clin Trials. 2011 May-Jun;12(3):131-40. doi: 10.1310/hct1203-131.

PMID:
21684853
12.

Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.

Mangiafico L, Perja M, Fusco F, Riva S, Mago D, Gringeri A.

Haemophilia. 2012 Jan;18(1):108-11. doi: 10.1111/j.1365-2516.2011.02610.x.

PMID:
21762404
13.

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL; Study 145 Team..

Lancet Infect Dis. 2012 Jan;12(1):27-35. doi: 10.1016/S1473-3099(11)70249-3.

PMID:
22015077
14.

Raltegravir: in treatment-naive patients with HIV-1 infection.

Croxtall JD, Scott LJ.

Drugs. 2010 Mar 26;70(5):631-42. doi: 10.2165/11204590-000000000-00000. Review.

PMID:
20329808
15.

Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy.

Ananworanich J, Gorowara M, Avihingsanon A, Kerr SJ, van Heesch N, Khongpetch C, Uanithirat A, Hill A, Ruxrungtham K, Burger DM; HIV-NAT 127 Study Team..

Antimicrob Agents Chemother. 2012 Apr;56(4):1892-8. doi: 10.1128/AAC.05694-11.

16.

A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.

Hatano H, Scherzer R, Wu Y, Harvill K, Maka K, Hoh R, Sinclair E, Palmer S, Martin JN, Busch MP, Deeks SG, Hsue PY.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):317-25. doi: 10.1097/QAI.0b013e31826e7d0f.

17.
18.

Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain.

Chaudhary MA, Moreno S, Kumar RN, Nocea G, Elbasha E.

AIDS Res Hum Retroviruses. 2009 Jul;25(7):679-89. doi: 10.1089/aid.2008.0254.

PMID:
19552590
19.

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Eron JJ Jr; ACTG A5262 Team..

AIDS. 2011 Nov 13;25(17):2113-22. doi: 10.1097/QAD.0b013e32834bbaa9.

20.

Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.

Wohl DA, Dumond JB, Blevins S, Pittard D, Ragan D, Wang R, Massengale K, Walsh K, Floris-Moore M, Eron JJ Jr, Richardson A, Hudgens MG, Kashuba AD.

Antimicrob Agents Chemother. 2013 Feb;57(2):784-8. doi: 10.1128/AAC.01826-12.

Supplemental Content

Support Center